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 Viral hepatitis caused by Hepatitis A, B or C virus 
infection is a significant cause of morbidity and 
mortality in Malaysia. The national incidence rate for 
hepatitis A has dropped steadily in conjunction with 
successful public health measures; nevertheless, 
hepatitis B and C incidence and its clinical outcome 
remain a concern for health authorities1. 
 In this study, previous hepatitis B (HBV) and C 
(HCV) virus prevalence in healthy Malaysian adults 
residing in Peninsular Malaysia was determined in a 
serosurvey. One thousand and twenty (1020) serum 
samples were randomly sampled from the Malaysian 
Cohort biobank. The Malaysian Cohort is a national 
project carried out to determine risk factors and 
biomarkers for diseases in the Malaysian population2 . 
For this serosurvey, samples were from participants 
aged 35-64 and residing in the states of Peninsular 
Malaysia. HBV and HCV prevalence of sampled 
subjects were determined using HBV surface antigen 
(HBsAg) and HCV antibody (HCV Ab) detection kits 
(RVR Diagnostics Sdn. Bhd., Malaysia), respectively. 
Briefly, 10ul of each tested serum was pipetted into the 
well of a test cartridge, which was later added with the 
kit’s diluent reagent. The sample and diluent mixture 
was then incubated for 10 minutes prior reading of test 
result. A double band on the cartridge (one band for 
control, another for sample positivity) indicates a 
positive result, while a single band is indicative of a 
negative outcome. The HBsAg kit has a sensitivity and 
specificity of 100%, while the HCV Ab kit has a 
sensitivity of 98.7% and specificity of 99.6%.    
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 Twenty-eight (28) or 2.8% serum samples were 
tested positive for HBsAg, while 10 (1.0%) samples 
were found to carry antibodies for HCV. No sample was 
positive for both HBsAG and HCV Ab. Interestingly, 
for the HBsAg positive samples, most (n=14, 50.0%) 
were from the older age group of 55-64 years old, and 
staying in rural areas (n= 18, 64.3%). While for the 
HCV seropositive subjects, most were from the older 
age group of 55-64 years old (n= 5, 50%), with more 
urbanites found to be seropositive (n= 6, 60%). 
 The prevalence of HBsAg in Malaysians was 
reported to be around 5 to 7% in the 1980s; this was 
before the nationwide implementation of hepatitis B 
vaccination for all new-born infants in 19893. Even 
though the vaccination drive was aimed at infants, some 
young adults during the 1980s also received the 
vaccination; this might have subsequently lowered the 
seroprevalence to 2.8% as found in this study4. 
However, a previous report estimated 2.5% of the 
Malaysian population aged 15-64 years old to be 
positive for HCV exposure, an estimate higher than the 
results obtained in this study5. Despite its low 
prevalence, HCV seropositivity remains a healthcare 
concern as no vaccine is yet available; and without 
active screening surveillance the infected are usually 
diagnosed at a later stage with cirrhosis or liver cancer. 
In Indonesia, to our knowledge, only one study on HCV 
seroprevalence was perform in healthy subjects, where 
2.2% were found to be HCV positive6; while HBsAg 
prevalence was found to be 1.1% in young adults of 
Singapore7. 
 This preliminary report shows low seroprevalence 
of HBV and HCV in adults residing in Peninsular 
Malaysia. A larger study involving representative 
participants for each demographic factor will be carried 
out in the future. 
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